Breaking News

WuXi STA, Antengene Ink Mfg. Pact

WuXi STA will provide in process R&D and manufacturing services

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, and Antengene Corp., have entered a strategic partnership for the CMC development and manufacturing of innovative oncology drugs. WuXi STA will provide in process R&D and manufacturing services using the MAH scheme to help accelerate new drug development.   Antengene is focused on the development of new drugs in China and the Asia-Pacific region through internal R&D as well as external partnerships. The company’s pipeline inclu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters